(Q34225850)

31 July 2017

The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis (English)

1 reference

31 July 2017

Stevens–Johnson syndrome

1 reference

Maja Mockenhaupt

1

1 reference

31 July 2017

1 November 2011

1 reference

Expert Review of Clinical Immunology

31 July 2017

1 reference

31 July 2017

7

1 reference

31 July 2017

6

1 reference

31 July 2017

803-13; quiz 814-5

1 reference

Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study

31 July 2017

1 reference

Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

Epidemiology of staphylococcal scalded skin syndrome in Germany

21 January 2018

1 reference

Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).

21 January 2018

1 reference

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis

21 January 2018

1 reference

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

21 January 2018

1 reference

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

21 January 2018

1 reference

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

21 January 2018

1 reference

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

21 January 2018

1 reference

Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

Drug hypersensitivity: pharmacogenetics and clinical syndromes

21 January 2018

1 reference

Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

21 January 2018

1 reference

Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series

21 January 2018

1 reference

Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset

21 January 2018

1 reference

Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date

21 January 2018

1 reference

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

21 January 2018

1 reference

SCORTEN: a severity-of-illness score for toxic epidermal necrolysis

21 January 2018

1 reference

Toxic epidermal necrolysis: does immunoglobulin make a difference?

21 January 2018

1 reference

Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis

21 January 2018

1 reference

Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

21 January 2018

1 reference

Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.11.66

1 reference

31 July 2017

1 reference

PubMed ID

22014021